Hormone Replacement Therapy

European authorities give the go-ahead to Angeliq

Published in OBGYN and Reproduction Week, August 4th, 2003

Schering AG, Germany, (SCH, SHR) announced that the European Union has positively concluded the Mutual Recognition Procedure for Schering's novel low dose hormone replacement therapy (HRT) product Angeliq.

After the decision is made, the European member states usually get the official certificate of approval within 3 months. The rollout of the pan European launch for Angeliq will begin this autumn. Schering received the first European approval for Angeliq in December 2002 in the Netherlands, which served as the reference member state for the Mutual Recognition Procedure (MRP).

Angeliq is a low-dose combination preparation and the only HRT product...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week

Source: OBGYN and Reproduction Week (2003-08-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry